Patents Represented by Attorney, Agent or Law Firm William Hare
  • 1-(4-Arylpiperazin-1-yl)-&ohgr;-[N-(&agr;,&ohgr;-dicarboximidoL)]-alkanes useful as uro-selective &agr;1-adrenoceptor blockers
    Patent number: 6812344
    Abstract: The present invention relates to certain novel piperazine derivatives having protracted uro-selective &agr;1-adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating benign prostratic hyperplasia (BPH). This invention also relates to methods for making the novel compounds, pharmaceutical compositions containing the compounds, and methods of treating benign prostatic hyperplasia using the compounds.
    Type: Grant
    Filed: May 24, 2000
    Date of Patent: November 2, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Nitya Anand, Neelima Sinha, Sanjay Jain, Anita Mehta, Anil Kumar Saxena
  • Process for the preparation of fluoxetine hydrochloride
    Patent number: 6677485
    Abstract: An improved and industrially advantageous process for the preparation of the antidepressant fluoxetine and its pharmaceutically acceptable salts, preferably hydrochloride.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: January 13, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Naresh Kumar, Bakthavathsalan Vijayaraghavan, Kinali Venkata Ramana, Swargam Sathyanarayana
  • Controlled release formulation
    Patent number: 6673369
    Abstract: The present invention relates to a controlled release pharmaceutical composition comprising amounts ranging from about 0.1 to about 4.5% w/w, of one or more of rate controlling cellulosic ether polymers.
    Type: Grant
    Filed: January 22, 2002
    Date of Patent: January 6, 2004
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashok Rampal, Rajeev S. Raghuvanshi, Manoj Kumar
  • Azole compounds as therapeutic agents for fungal infections
    Patent number: 6670363
    Abstract: The present invention relates to the derivatives of specially substituted azole compounds which have improved antifungal activity as compared to known compounds such as fluconazole and itraconazole and the processes for the preparation thereof. This invention also relates to pharmaceutical compositions containing the compounds of the present invention and their use in treating and/or preventing fungal infections in mammals, preferably humans.
    Type: Grant
    Filed: May 22, 2000
    Date of Patent: December 30, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Ashwani Kumar Verma, Sudershan K. Arora, Jasbir Singh Arora, Ashok Rattan
  • Derivatives of monosaccharides as cell adhesion inhibitors
    Patent number: 6590085
    Abstract: This invention relates generally to compounds and processes for synthesizing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid. The compounds of this invention are useful, inter-alia, for the inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies, including inflammatory and autoimmune diseases, such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection and psoriasis. This invention also relates to pharmacological compositions containing derivatives of 2-3-O-isopropylidene-&agr;-L-xylo-2-hexulofuranosonic acid and the methods of treating such pathologies as listed above.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: July 8, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Sudershan K Arora, Nawal Kishore, Jang Bahadur Gupta, Vishwas D Joshi
  • Extended release formulation of etodolac
    Patent number: 6586005
    Abstract: A sustained release formulation of etodolac for once daily administration is described.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: July 1, 2003
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Rajeev S. Raghuvanshi, Ashok Rampal, Himadri Sen